Faruqi & Faruqi, LLP Investigates MoonLake Immunotherapeutics Claims for Investors
On November 21, 2025, the national securities law firm Faruqi & Faruqi, LLP announced its investigation into potential claims against MoonLake Immunotherapeutics, Inc., also known as Reuters Research Inc. (NASDAQ: MLTX). The firm is calling on investors who purchased or acquired securities in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal rights and options in light of the company's troubling performance. This investigation comes as a reminder to investors of the approaching deadline of December 15, 2025, for those interested in taking on the role of lead plaintiff in a federal securities class action lawsuit.
The complaint filed against MoonLake alleges serious violations of federal securities laws, citing that the company and several of its executives made false and misleading statements about their products and failed to disclose crucial facts regarding their Nanobodies, particularly in comparison to monoclonal antibodies. Some of the specific allegations include:
1. Both SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F)
2. The so-called distinctive Nanobody structure of SLK may not provide any clinical advantages over the established monoclonal structure of BIMZELX
3. The supposed superior tissue penetration offered by SLK does not necessarily correlate to improved clinical efficacy
4. Consequently, the positive claims regarding SLK's advantages over monoclonal antibodies lacked a plausible foundation.
On September 28, 2025, the situation escalated as MoonLake published results from the week-16 analysis of their Phase 3 VELA program, revealing that SLK did not demonstrate competitive efficacy against BIMZELX. This announcement led to a catastrophic decline in MoonLake's stock price, which plummeted by an astonishing $55.75 per share, a drop of 89.9%, closing at $6.24 on September 29, 2025.
Faruqi & Faruqi emphasizes that the lead plaintiff is typically the investor who has the largest financial stake in the compensation sought by the class and is capable of adequately representing class members. Investors can take action by either moving to serve as the lead plaintiff through their counsel or choosing to remain as absent class members. It's crucial to understand that one’s ability to participate in any recovery is not influenced by their decision regarding lead plaintiff status.
Furthermore, the firm encourages anyone with knowledge of MoonLake's practices—including whistleblowers, former employees, and shareholders—to reach out to them for assistance. Those interested in learning more about the ongoing class action related to MoonLake Immunotherapeutics can visit www.faruqilaw.com/MLTX or directly contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
Overall, this development calls for urgent attention from investors affected by these allegations, particularly as the deadline to potentially join a securities class action approaches. As this situation continues to unfold, updates can also be found on social media platforms such as LinkedIn, X, and Facebook. As with all legal matters, the law firm promises to treat all communications confidentially, signaling its commitment to protecting the interests of its clients.
The complaint filed against MoonLake alleges serious violations of federal securities laws, citing that the company and several of its executives made false and misleading statements about their products and failed to disclose crucial facts regarding their Nanobodies, particularly in comparison to monoclonal antibodies. Some of the specific allegations include:
1. Both SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F)
2. The so-called distinctive Nanobody structure of SLK may not provide any clinical advantages over the established monoclonal structure of BIMZELX
3. The supposed superior tissue penetration offered by SLK does not necessarily correlate to improved clinical efficacy
4. Consequently, the positive claims regarding SLK's advantages over monoclonal antibodies lacked a plausible foundation.
On September 28, 2025, the situation escalated as MoonLake published results from the week-16 analysis of their Phase 3 VELA program, revealing that SLK did not demonstrate competitive efficacy against BIMZELX. This announcement led to a catastrophic decline in MoonLake's stock price, which plummeted by an astonishing $55.75 per share, a drop of 89.9%, closing at $6.24 on September 29, 2025.
Faruqi & Faruqi emphasizes that the lead plaintiff is typically the investor who has the largest financial stake in the compensation sought by the class and is capable of adequately representing class members. Investors can take action by either moving to serve as the lead plaintiff through their counsel or choosing to remain as absent class members. It's crucial to understand that one’s ability to participate in any recovery is not influenced by their decision regarding lead plaintiff status.
Furthermore, the firm encourages anyone with knowledge of MoonLake's practices—including whistleblowers, former employees, and shareholders—to reach out to them for assistance. Those interested in learning more about the ongoing class action related to MoonLake Immunotherapeutics can visit www.faruqilaw.com/MLTX or directly contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
Overall, this development calls for urgent attention from investors affected by these allegations, particularly as the deadline to potentially join a securities class action approaches. As this situation continues to unfold, updates can also be found on social media platforms such as LinkedIn, X, and Facebook. As with all legal matters, the law firm promises to treat all communications confidentially, signaling its commitment to protecting the interests of its clients.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.